Aevi Genomic Medicine (GNMX) Earning Somewhat Favorable News Coverage, Study Shows
News headlines about Aevi Genomic Medicine (NASDAQ:GNMX) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aevi Genomic Medicine earned a media sentiment score of 0.00 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.1317875980384 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Aevi Genomic Medicine (GNMX) opened at $1.47 on Monday. Aevi Genomic Medicine has a fifty-two week low of $0.98 and a fifty-two week high of $6.89.
Aevi Genomic Medicine (NASDAQ:GNMX) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.01). During the same quarter last year, the business earned ($0.29) EPS. equities research analysts forecast that Aevi Genomic Medicine will post -0.88 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on the stock. Needham & Company LLC dropped their target price on shares of Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, August 16th. Jefferies Group LLC reissued a “hold” rating and issued a $1.50 target price on shares of Aevi Genomic Medicine in a research report on Monday, August 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $7.50.
COPYRIGHT VIOLATION WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/11/20/aevi-genomic-medicine-gnmx-earning-somewhat-favorable-news-coverage-study-shows.html.
In other news, CEO Michael F. Cola bought 119,047 shares of Aevi Genomic Medicine stock in a transaction on Tuesday, October 17th. The stock was purchased at an average cost of $1.26 per share, with a total value of $149,999.22. Following the purchase, the chief executive officer now directly owns 218,483 shares of the company’s stock, valued at approximately $275,288.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Garry Arthur Neil bought 75,000 shares of Aevi Genomic Medicine stock in a transaction on Tuesday, October 17th. The shares were purchased at an average cost of $1.26 per share, with a total value of $94,500.00. Following the completion of the purchase, the insider now directly owns 114,774 shares in the company, valued at $144,615.24. The disclosure for this purchase can be found here. Insiders have acquired a total of 625,440 shares of company stock valued at $787,433 over the last three months. 15.20% of the stock is currently owned by company insiders.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.